###begin article-title 0
Comprehensive Biostatistical Analysis of CpG Island Methylator Phenotype in Colorectal Cancer Using a Large Population-Based Sample
###end article-title 0
###begin p 1
Conceived and designed the experiments: CF SO. Performed the experiments: KN NI KS SK GJK JQ SO. Analyzed the data: KN NI KS SK GJK ESS AH DJH JQ DS EG CF SO. Contributed reagents/materials/analysis tools: GJK ESS AH JQ DS SO. Wrote the paper: KN NI KS SK DJH JQ EG CF SO.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 120 124 120 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 200 207 200 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CACNA1G</italic>
###xml 209 213 209 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF2</italic>
###xml 215 222 215 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NEUROG1</italic>
###xml 224 229 224 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RUNX3</italic>
###xml 234 239 234 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOCS1</italic>
The CpG island methylator phenotype (CIMP) is a distinct phenotype associated with microsatellite instability (MSI) and BRAF mutation in colon cancer. Recent investigations have selected 5 promoters (CACNA1G, IGF2, NEUROG1, RUNX3 and SOCS1) as surrogate markers for CIMP-high. However, no study has comprehensively evaluated an expanded set of methylation markers (including these 5 markers) using a large number of tumors, or deciphered the complex clinical and molecular associations with CIMP-high determined by the validated marker panel.
###end p 3
###begin title 4
Metholodology/Principal Findings
###end title 4
###begin p 5
###xml 52 58 52 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 66 70 66 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHFR</italic>
###xml 72 78 72 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRABP1</italic>
###xml 80 84 80 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIC1</italic>
###xml 86 92 86 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 94 98 94 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MGMT</italic>
###xml 115 119 115 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 126 132 126 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 142 145 142 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WRN</italic>
###xml 284 291 284 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CACNA1G</italic>
###xml 293 297 293 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF2</italic>
###xml 299 306 299 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NEUROG1</italic>
###xml 308 313 308 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RUNX3</italic>
###xml 318 323 318 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOCS1</italic>
###xml 326 332 326 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 334 340 334 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRABP1</italic>
###xml 350 354 350 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 364 367 364 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WRN</italic>
###xml 426 430 426 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 441 445 441 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 809 813 809 813 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 884 890 881 887 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CTNNB1</italic>
###xml 1098 1102 1095 1099 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
DNA methylation at 16 CpG islands [the above 5 plus CDKN2A (p16), CHFR, CRABP1, HIC1, IGFBP3, MGMT, MINT1, MINT31, MLH1, p14 (CDKN2A/ARF) and WRN] was quantified in 904 colorectal cancers by real-time PCR (MethyLight). In unsupervised hierarchical clustering analysis, the 5 markers (CACNA1G, IGF2, NEUROG1, RUNX3 and SOCS1), CDKN2A, CRABP1, MINT31, MLH1, p14 and WRN were generally clustered with each other and with MSI and BRAF mutation. KRAS mutation was not clustered with any methylation marker, suggesting its association with a random methylation pattern in CIMP-low tumors. Utilizing the validated CIMP marker panel (including the 5 markers), multivariate logistic regression demonstrated that CIMP-high was independently associated with older age, proximal location, poor differentiation, MSI-high, BRAF mutation, and inversely with LINE-1 hypomethylation and beta-catenin (CTNNB1) activation. Mucinous feature, signet ring cells, and p53-negativity were associated with CIMP-high in only univariate analysis. In stratified analyses, the relations of CIMP-high with poor differentiation, KRAS mutation and LINE-1 hypomethylation significantly differed according to MSI status.
###end p 5
###begin title 6
Conclusions
###end title 6
###begin p 7
###xml 235 239 235 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
Our study provides valuable data for standardization of the use of CIMP-high-specific methylation markers. CIMP-high is independently associated with clinical and key molecular features in colorectal cancer. Our data also suggest that KRAS mutation is related with a random CpG island methylation pattern which may lead to CIMP-low tumors.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 72 75 72 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Jones1">[1]</xref>
###xml 77 80 77 80 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Esteller1">[2]</xref>
###xml 165 168 165 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Baylin1">[3]</xref>
###xml 170 173 170 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Issa1">[4]</xref>
###xml 314 317 314 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Issa1">[4]</xref>
###xml 318 321 318 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Teodoridis1">[7]</xref>
###xml 488 492 488 492 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 544 548 544 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 600 603 597 600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Toyota2">[8]</xref>
###xml 604 608 601 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Barault1">[23]</xref>
###xml 51 56 <span type="species:ncbi:9606">human</span>
Epigenetic aberrations are important mechanisms in human carcinogenesis [1], [2]. A number of tumor suppressor genes are silenced by promoter CpG island methylation [3], [4]. A subset of colorectal cancers exhibit widespread promoter methylation, which is referred to as the CpG island methylator phenotype (CIMP) [4]-[7]. CIMP-high colorectal tumors have been associated with older age, female sex, proximal location, mucinous and poor differentiation, microsatellite instability (MSI), BRAF mutation, high LINE-1 methylation level, wild-type TP53, stable chromosomes, and inactive WNT/beta-catenin [8]-[23]. However, many of these features are interrelated, and thus, it is essential to analyze a large number of tumors by multivariate analysis to decipher the complex relations between CIMP-high and these clinical/tumoral variables.
###end p 9
###begin p 10
###xml 165 169 165 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Weisenberger1">[15]</xref>
###xml 339 342 339 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Teodoridis1">[7]</xref>
###xml 364 368 364 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Weisenberger1">[15]</xref>
###xml 421 428 421 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CACNA1G</italic>
###xml 430 434 430 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF2</italic>
###xml 436 443 436 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NEUROG1</italic>
###xml 445 450 445 450 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RUNX3</italic>
###xml 455 460 455 460 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOCS1</italic>
###xml 580 586 580 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 594 600 594 600 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRABP1</italic>
###xml 605 609 605 609 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 643 647 643 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Ogino3">[24]</xref>
There is considerable heterogeneity of tumors with regard to CpG island methylation, and not all CpG islands are methylated in a similar manner in colorectal cancer [15]. Thus, choice of CpG islands can substantially influence the features of CIMP. In fact, different CIMP panels used in various studies have caused considerable confusion [7]. Weisenberger et al. [15] have screened 195 CpG islands, and selected 5 loci (CACNA1G, IGF2, NEUROG1, RUNX3 and SOCS1), which can serve as surrogate markers for CIMP-high. We have further validated the use of 8 markers (the above 5 plus CDKN2A (p16), CRABP1 and MLH1) as a CIMP-high diagnostic panel [24]. However, no study has comprehensively compared these CIMP-high-specific CpG islands and other CpG islands using a large number of tumors.
###end p 10
###begin p 11
In this study, we have assessed 16 CpG islands including the new 5 CIMP markers as well as MINT (methylated in tumor) markers and other CpG islands, utilizing hierarchical clustering analysis on a large number of colorectal cancers. We have also assessed the characteristics of CIMP-high tumors determined by a validated marker panel, and interactions of various clinical and tumoral factors by multivariate logistic regression analysis. This study provides the rationale for standardization of CIMP-high-specific methylation markers.
###end p 11
###begin title 12
Methods
###end title 12
###begin title 13
Study Group
###end title 13
###begin p 14
###xml 137 141 137 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Colditz1">[25]</xref>
###xml 143 147 143 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Chan1">[26]</xref>
###xml 237 241 237 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Chan1">[26]</xref>
###xml 705 709 705 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Colditz1">[25]</xref>
###xml 711 715 711 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Chan1">[26]</xref>
###xml 1143 1150 1143 1150 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 1</bold>
###xml 1143 1150 1143 1150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003698-t001"><bold>Table 1</bold></xref>
###xml 1361 1365 1361 1365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Chan1">[26]</xref>
###xml 1441 1445 1441 1445 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1447 1451 1447 1451 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 1528 1532 1525 1529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Kawasaki1">[19]</xref>
###xml 1534 1538 1531 1535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Ogino2">[21]</xref>
###xml 1540 1544 1537 1541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Ogino3">[24]</xref>
###xml 1546 1550 1543 1547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Kawasaki2">[27]</xref>
###xml 2146 2150 2143 2147 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 2152 2156 2149 2153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 110 115 <span type="species:ncbi:9606">women</span>
###xml 212 215 <span type="species:ncbi:9606">men</span>
###xml 262 274 <span type="species:ncbi:9606">participants</span>
###xml 558 570 <span type="species:ncbi:9606">participants</span>
###xml 853 865 <span type="species:ncbi:9606">participants</span>
###xml 1027 1030 <span type="species:ncbi:9606">men</span>
###xml 1057 1062 <span type="species:ncbi:9606">women</span>
###xml 2547 2552 <span type="species:ncbi:10090">mouse</span>
###xml 2716 2721 <span type="species:ncbi:9606">Women</span>
We utilized the databases of two large prospective cohort studies; the Nurses' Health Study (NHS, N = 121,700 women followed since 1976) [25], [26], and the Health Professionals Follow-up Study (HPFS, N = 51,500 men followed since 1986) [26]. A subset of cohort participants developed colorectal cancer during prospective follow-up. Thus, these colorectal cancers represented a population-based, relatively unbiased sample (compared to a single or few-hospital-based sample). Previous studies on the cohorts have described baseline characteristics of cohort participants and incident colorectal cancer cases, and confirmed that our colorectal cancers were well representative as a population-based sample [25], [26]. Clinical information was obtained through chart review by physicians. We collected paraffin-embedded tissue blocks from hospitals where participants had undergone resections of primary colorectal cancers. Based on availability of adequate tissue specimens, a total of 904 colorectal cancer cases (406 from the men's cohort and 498 from the women's cohort) were included. Clinical characteristics of the cases are described in Table 1 (on the left, under the column heading "All cases"). Among our cohort studies, there was no significant difference in demographic features between cases with tissue available and those without available tissue [26]. Most tumors have previously been characterized for statuses of MSI, CIMP, KRAS, BRAF, p53, beta-catenin, LINE-1 methylation and 14 of the 16 methylation markers [19], [21], [24], [27]. However, none of our previous studies have comprehensively analyzed the 16 methylation markers in relation to each other, independent associations of CIMP with various clinical, pathological or tumoral molecular characteristics, or interactions of various factors on the associations with CIMP-high by comprehensive biostatistical methods. This study represents a unique novel study in term of 1) a large sample size; 2) the validated set of CIMP-specific methylation markers; 3) the number of other molecular events analyzed, including 8 CpG islands other than the CIMP-specific markers, MSI, KRAS, BRAF, p53, LINE-1 methylation and beta-catenin; and 4) comprehensive statistical analyses including unsupervised hierarchical clustering, smoothing splines to assess nonlinearity, multivariate logistic regression, and stratified logistic regression. Thus, this study obtained novel data from the existing materials and database, analogous to novel studies using the well-described cell lines or mouse models. Informed consent was obtained from all study subjects. Tissue collection and analyses were approved by the Harvard School of Public Health and Brigham and Women's Hospital Institutional Review Boards.
###end p 14
###begin title 15
Clinical, pathologic and molecular characteristics of colon cancer cases according to CIMP status.
###end title 15
###begin p 16
(%) indicates the proportion of cases with a specific clinical feature within each MSI/CIMP subtype.
###end p 16
###begin p 17
Proximal colon includes cecum to transverse colon, and distal colon includes splenic flexure to sigmoid colon.
###end p 17
###begin p 18
###xml 311 315 297 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Jass1">[35]</xref>
p53 and beta-catenin status was determined by immunohistochemistry. Active beta-catenin was defined as beta-catenin score >/=3, where the beta-catenin score was the sum of nuclear (0, 1+ or 2+), cytoplasmic (0, 1+ or 2+) and membrane (0 or 1+ if expression is lost) scores as originally described by Jass et al.[35].
###end p 18
###begin p 19
t-test assuming unequal variances.
###end p 19
###begin p 20
CIMP, CpG island methylator phenotype; LINE-1, long interspersed nucleotide element-1; MSI, microsatellite instability; SD, standard deviation.
###end p 20
###begin title 21
###xml 57 61 57 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 66 70 66 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
Pathologic Examination, DNA Extraction and Sequencing of KRAS and BRAF
###end title 21
###begin p 22
###xml 308 312 308 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 335 339 335 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 389 393 389 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Ogino4">[28]</xref>
###xml 395 399 395 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Ogino5">[29]</xref>
For all cases, pathologic features including tumor differentiation, mucinous features and signet ring cells were examined by a pathologist (S.O.). Poor differentiation was defined as the presence of <50% glandular area. Genomic DNA was extracted from paraffin tissue, and PCR and Pyrosequencing targeted for KRAS codons 12 and 13, and BRAF codon 600 were performed as previously described [28], [29].
###end p 22
###begin title 23
Microsatellite Instability (MSI) Analysis
###end title 23
###begin p 24
###xml 182 186 182 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Ogino3">[24]</xref>
MSI status was determined by the MSI panel including D2S123, D5S346, D17S250, BAT25, BAT26, BAT40, D18S55, D18S56, D18S67 and D18S487 (i.e., 10-marker panel) as previously described [24]. A "high degree of MSI" (MSI-high) was defined as the presence of instability in >/=30% of the markers.
###end p 24
###begin title 25
Real-time PCR (MethyLight) for Quantitative DNA Methylation Analysis
###end title 25
###begin p 26
###xml 75 79 75 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Eads1">[30]</xref>
###xml 133 137 133 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Ogino6">[31]</xref>
###xml 199 206 199 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CACNA1G</italic>
###xml 208 212 208 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF2</italic>
###xml 214 221 214 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NEUROG1</italic>
###xml 223 228 223 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RUNX3</italic>
###xml 233 238 233 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOCS1</italic>
###xml 266 272 266 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 280 284 280 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHFR</italic>
###xml 286 292 286 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRABP1</italic>
###xml 294 298 294 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIC1</italic>
###xml 300 306 300 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 308 312 308 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MGMT</italic>
###xml 329 333 329 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 340 346 340 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 357 360 357 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WRN</italic>
###xml 363 369 363 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL2A1</italic>
###xml 467 471 467 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Ogino6">[31]</xref>
###xml 518 522 518 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Weisenberger1">[15]</xref>
###xml 524 528 524 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Kawasaki2">[27]</xref>
###xml 541 547 541 547 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 557 560 557 560 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WRN</italic>
###xml 576 577 576 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 576 577 576 577 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>T</italic></bold>
###xml 579 580 579 580 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 579 580 579 580 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>T</italic></bold>
###xml 593 594 593 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 593 594 593 594 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>T</italic></bold>
###xml 572 603 572 603 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-G<bold><italic>T</italic></bold>T <bold><italic>T</italic></bold>CG GGC GTG AG<bold><italic>T</italic></bold> ACG A-3&#8242;</named-content>
###xml 664 666 664 666 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AA</italic>
###xml 664 666 664 666 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>AA</italic></bold>
###xml 671 672 671 672 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 671 672 671 672 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>A</italic></bold>
###xml 677 678 677 678 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 677 678 677 678 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>A</italic></bold>
###xml 678 678 678 678 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"/>
###xml 678 679 678 679 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 678 679 678 679 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>A</italic></bold>
###xml 684 685 684 685 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 684 685 684 685 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>A</italic></bold>
###xml 688 689 688 689 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 688 689 688 689 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>A</italic></bold>
###xml 663 691 663 691 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">G<bold><italic>AA</italic></bold> TCG <bold><italic>A</italic></bold>CG CA<bold><italic>A</italic></bold><italic/><bold><italic>A</italic></bold>CA CG<bold><italic>A</italic></bold> CT<bold><italic>A</italic></bold> C</named-content>
###xml 742 743 742 743 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 742 743 742 743 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>T</italic></bold>
###xml 747 748 747 748 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 747 748 747 748 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>T</italic></bold>
###xml 751 752 751 752 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 751 752 751 752 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>T</italic></bold>
###xml 754 755 754 755 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 754 755 754 755 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>T</italic></bold>
###xml 737 781 737 781 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">6FAM-<bold><italic>T</italic></bold>CG G<bold><italic>T</italic></bold>T G<bold><italic>T</italic></bold>T <bold><italic>T</italic></bold>AG GGC GAA GTA CGG G-BHQ-1</named-content>
###xml 909 910 909 910 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 909 910 909 910 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>T</italic></bold>
###xml 930 931 930 931 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 930 931 930 931 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>T</italic></bold>
###xml 905 937 905 937 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;- <bold><italic>T</italic></bold>TG GAG GCG GCG AGA A<bold><italic>T</italic></bold>A T-3&#8242;</named-content>
###xml 1004 1005 1004 1005 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 1004 1005 1004 1005 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>A</italic></bold>
###xml 1006 1007 1006 1007 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 1006 1007 1006 1007 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>A</italic></bold>
###xml 1014 1015 1014 1015 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 1014 1015 1014 1015 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>A</italic></bold>
###xml 1015 1015 1015 1015 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"/>
###xml 1015 1016 1015 1016 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 1015 1016 1015 1016 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>A</italic></bold>
###xml 1019 1020 1019 1020 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 1019 1020 1019 1020 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>A</italic></bold>
###xml 992 1023 992 1023 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;- CCC CGT <bold><italic>A</italic></bold>A<bold><italic>A</italic></bold> CCG CG<bold><italic>A</italic></bold><italic/><bold><italic>A</italic></bold>AT <bold><italic>A</italic></bold>-3&#8242;</named-content>
###xml 1075 1077 1075 1077 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TT</italic>
###xml 1075 1077 1075 1077 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>TT</italic></bold>
###xml 1080 1081 1080 1081 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 1080 1081 1080 1081 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>T</italic></bold>
###xml 1062 1110 1062 1110 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">6FAM-5&#8242;- CGG <bold><italic>TT</italic></bold>C G<bold><italic>T</italic></bold>C GCG AGT GAG GGT T-3&#8242; &#8211;BHQ-1</named-content>
###xml 1149 1150 1149 1150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 1149 1150 1149 1150 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>T</italic></bold>
###xml 1156 1158 1156 1158 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TT</italic>
###xml 1156 1158 1156 1158 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>TT</italic></bold>
###xml 1168 1171 1168 1171 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TTT</italic>
###xml 1168 1171 1168 1171 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>TTT</italic></bold>
###xml 1173 1174 1173 1174 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 1173 1174 1173 1174 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>T</italic></bold>
###xml 1145 1177 1145 1177 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-G<bold><italic>T</italic></bold>A TCG <bold><italic>TT</italic></bold>C GCG GCG <bold><italic>TTT</italic></bold> A<bold><italic>T</italic></bold>-3&#8242;</named-content>
###xml 1239 1240 1239 1240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 1239 1240 1239 1240 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>A</italic></bold>
###xml 1243 1246 1243 1246 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">AAA</italic>
###xml 1243 1246 1243 1246 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>AAA</italic></bold>
###xml 1251 1252 1251 1252 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 1251 1252 1251 1252 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>A</italic></bold>
###xml 1253 1254 1253 1254 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 1253 1254 1253 1254 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>A</italic></bold>
###xml 1263 1264 1263 1264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</italic>
###xml 1263 1264 1263 1264 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>A</italic></bold>
###xml 1236 1272 1236 1272 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-<bold><italic>A</italic></bold>CG <bold><italic>AAA</italic></bold> CCG <bold><italic>A</italic></bold>T<bold><italic>A</italic></bold> TCC GAA <bold><italic>A</italic></bold>TC A -3&#8242;</named-content>
###xml 1321 1324 1321 1324 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TTT</italic>
###xml 1321 1324 1321 1324 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>TTT</italic></bold>
###xml 1324 1324 1324 1324 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"/>
###xml 1324 1325 1324 1325 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 1324 1325 1324 1325 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>T</italic></bold>
###xml 1326 1327 1326 1327 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 1326 1327 1326 1327 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>T</italic></bold>
###xml 1327 1327 1327 1327 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"/>
###xml 1327 1328 1327 1328 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 1327 1328 1327 1328 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>T</italic></bold>
###xml 1335 1336 1335 1336 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 1335 1336 1335 1336 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>T</italic></bold>
###xml 1339 1340 1339 1340 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</italic>
###xml 1339 1340 1339 1340 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>T</italic></bold>
###xml 1316 1352 1316 1352 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">6FAM-<bold><italic>TTT</italic></bold><italic/><bold><italic>T</italic></bold>T<bold><italic>T</italic></bold><italic/><bold><italic>T</italic></bold>TG CGG <bold><italic>T</italic></bold>CG <bold><italic>T</italic></bold>TG CGG G-BHQ</named-content>
###xml 1605 1611 1587 1593 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COL2A1</italic>
###xml 1839 1850 1821 1832 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GENE:COL2A1</italic>
###xml 1896 1907 1878 1889 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GENE:COL2A1</italic>
###xml 1937 1940 1919 1922 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sss</italic>
###xml 2099 2103 2079 2083 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Ogino6">[31]</xref>
###xml 1635 1640 <span type="species:ncbi:9606">human</span>
###xml 1950 1955 <span type="species:ncbi:9606">human</span>
Sodium bisulfite treatment on DNA and subsequent real-time PCR (MethyLight [30]) was validated and performed as previously described [31]. We quantified DNA methylation in 5 CIMP-specific promoters (CACNA1G, IGF2, NEUROG1, RUNX3 and SOCS1) and 11 other CpG islands [CDKN2A (p16), CHFR, CRABP1, HIC1, IGFBP3, MGMT, MINT1, MINT31, MLH1, p14 (CDKN2A/ARF), and WRN]. COL2A1 (the collagen 2A1 gene) was used to normalize for the amount of template bisulfite-converted DNA [31]. Primers and probes were previously described [15], [27], except for IGFBP3, p14 and WRN: IGFBP3-F, 5'-GTT TCG GGC GTG AGT ACG A-3' (Genbank No. M35878, nucleotide Nos. 1692-1710); IGFBP3-R, GAA TCG ACG CAAACA CGA CTA C(nucleotide Nos. 1789-1810) and IGFBP3-probe, 6FAM-TCG GTT GTT TAG GGC GAA GTA CGG G-BHQ-1(nucleotide Nos. 1760-1784) (bisulfite-converted nucleotides are highlighted by bold face and italics); P14 (CDKN2A/ARF)-F, 5'- TTG GAG GCG GCG AGA ATA T-3' (Genbank No. L41934, nucleotide Nos. 238-256); P14-R, 5'- CCC CGT AAA CCG CGAAAT A-3' (nucleotide Nos. 332-350); P14-probe, 6FAM-5'- CGG TTC GTC GCG AGT GAG GGT T-3' -BHQ-1 (nucleotide Nos. 299-320); WRN-F, 5'-GTA TCG TTC GCG GCG TTT AT-3' (Genbank No. AY442327, nucleotide Nos. 1827-1846); WRN-R, 5'-ACG AAA CCG ATA TCC GAA ATC A -3' (nucleotide Nos. 1887-1908) and WRN-probe, 6FAM-TTTTTTTTG CGG TCG TTG CGG G-BHQ-(nucleotide Nos. 1855-1876). The PCR condition was initial denaturation at 95degreesC for 10 min followed by 45 cycles of 95degreesC for 15 sec and 60degreesC for 1 min. A standard curve was made for each PCR plate by duplicated PCR amplifications for COL2A1 on bisulfite-converted human genomic DNA at 4 different concentrations (in a 5-fold dilution series). The percentage of methylated reference (PMR, i.e., degree of methylation) at a specific locus was calculated by dividing the GENE:COL2A1 ratio of template amounts in a sample by the GENE:COL2A1 ratio of template amounts in SssI-treated human genomic DNA (presumably fully methylated) and multiplying this value by 100. Methylation positivity was set as PMR>/=4 as previously validated [31].
###end p 26
###begin title 27
Pyrosequencing to Measure LINE-1 Methylation
###end title 27
###begin p 28
###xml 126 130 126 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Ogino2">[21]</xref>
###xml 310 314 310 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Yang1">[32]</xref>
###xml 316 320 316 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Estecio1">[33]</xref>
In order to accurately quantify relatively high LINE-1 methylation levels, we utilized Pyrosequencing as previously described [21]. LINE-1 methylation level measured by Pyrosequencing has been shown to correlate well with overall 5-methylcytosine level (i.e., genome-wide DNA methylation level) in tumor cells [32], [33].
###end p 28
###begin title 29
Immunohistochemistry for p53 and beta-catenin
###end title 29
###begin p 30
###xml 131 135 128 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Kawasaki1">[19]</xref>
###xml 137 141 134 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Ogino7">[34]</xref>
###xml 637 641 628 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Jass1">[35]</xref>
Tissue microarrays (TMAs) were constructed and immunohistochemistry for p53 and beta-catenin was performed as previously described [19], [34]. Appropriate positive and negative controls were included in each run of immunohistochemistry. Cytoplasmic and nuclear beta-catenin expression was recorded separately as either no expression (0), weak expression (1+), or moderate/strong expression (2+). The beta-catenin activation score was calculated as the sum of nuclear score (0-2), cytoplasmic score (0-2) and membrane score (0 if membrane staining was positive, +1 if membrane expression was lost), as originally described by Jass et al. [35]. All immunohistochemically-stained slides were examined by one of the investigator (beta-catenin by K.N.; p53 by S.O.) unaware of other data. Random samples of 402 and 118 tumors were re-examined for beta-catenin and p53, respectively, by a second observer (beta-catenin by S.O., p53 by K.N.) unaware of other data, and the concordances between the two observers were 0.83 for beta-catenin (kappa = 0.65, p<0.0001), and 0.87 for p53 (kappa = 0.75, p<0.0001), indicating substantial agreement.
###end p 30
###begin title 31
Statistical Analysis
###end title 31
###begin p 32
###xml 78 82 78 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 87 91 87 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 203 207 203 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Saeed1">[36]</xref>
For cluster analysis of biomarkers including the 16 methylation markers, MSI, KRAS and BRAF, we utilized average linkage hierarchical clustering with a Euclidean distance metric as implemented in MeV () [36]. The chi square test was used to examine an association between CIMP and other categorical variables of interest. The t-test assuming unequal variances was performed to compare mean age and mean LINE-1 methylation level. The kappa coefficient was calculated to assess agreement between each of the 16 markers (positive vs. negative) and the 16-marker CIMP panel (CIMP-high positive vs. negative).
###end p 32
###begin p 33
###xml 329 333 329 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 335 339 335 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
To examine the relations of a given variable and CIMP-high, we utilized unconditional logistic regression models to calculate odds ratios (ORs) for CIMP-high, according to the status of the given variable, unadjusted and adjusted for age, sex, tumor location, stage, differentiation, LINE-1 methylation level, and status of MSI, KRAS, BRAF, p53 and beta-catenin. To adjust for potential confounding, age and LINE-1 methylation level were used as continuous variables, and all of the other variables were used as categorical variables.
###end p 33
###begin p 34
###xml 592 596 592 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Durrleman1">[37]</xref>
For age and LINE-1, we assessed non-linearity by the likelihood ratio test that compared a regression model including a quadratic (or cubic) term with a model excluding it. The likelihood ratio test showed that including the quadratic term did not significantly alter model fit (p = 0.86 for age, p = 0.078 for LINE-1), and that including the cubic term did not significantly alter model fit (p = 0.87 for age, p = 0.084 for LINE-1). We also examined the possibility of a non-linear relation between age (or LINE-1 methylation) and CIMP-high, non-parametrically with restricted cubic splines [37].
###end p 34
###begin p 35
###xml 200 204 200 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 230 234 230 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 398 405 393 400 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 2</bold>
###xml 398 405 393 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003698-t002"><bold>Table 2</bold></xref>
###xml 763 770 756 763 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 2</bold>
###xml 763 770 756 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003698-t002"><bold>Table 2</bold></xref>
We dichotomized tumor location (proximal vs. distal), tumor differentiation (poor vs. well/moderate), signet ring cells (present vs. absent), MSI (high vs. non-MSI-high), p53 (positive vs. negative), KRAS (mutated vs. wild-type), BRAF (mutated vs. wild-type) and beta-catenin (active vs. inactive). There were 3 categories for mucinous feature (0%, 1-49%, and >/=50%) in the initial main analysis (Table 2). We dichotomized mucinous feature (present vs. absent) in secondary stratified analyses and analyses of interactions, because multivariate ORs for CIMP-high were similar across the 1-49% mucinous and >/=50% mucinous categories (in reference to the non-mucinous category). There were 4 categories for stage (I, II, III and IV) in the initial main analysis (Table 2). We dichotomized tumor stage (I vs. II-IV) in secondary stratified analyses and analyses of interactions, because multivariate ORs for CIMP-high were similar across stage II-IV (in reference to stage I).
###end p 35
###begin title 36
Associations with CIMP-high in colorectal cancer by univariate and multivariate analyses.
###end title 36
###begin p 37
###xml 144 148 144 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
Multivariate logistic regression model includes all of the above variables. Note that female, tumor stage, signet ring cells, mucinous feature, KRAS and p53 are not significantly related with CIMP-high after adjusting for other variables.
###end p 37
###begin p 38
###xml 217 221 206 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Jass1">[35]</xref>
beta-catenin activation is defined as beta-catenin score >/=3. The beta-catenin score is the sum of nuclear (0, 1+ or 2+), cytoplasmic (0, 1+ or 2+) and membrane (0 or 1+) scores as originally described by Jass et al.[35].
###end p 38
###begin p 39
Proximal colon includes cecum to transverse colon, and distal colon includes splenic flexure to rectum.
###end p 39
###begin p 40
CI, confidence interval; CIMP, CpG island methylator phenotype; LINE-1, long interspersed nucleotide element-1; MSI, microsatellite instability; OR, odds ratio.
###end p 40
###begin p 41
###xml 120 124 120 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 143 147 143 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
When there was missing information on tumor stage (12%), LINE-1 (3.9% missing), MSI (3.2% missing), p53 (1.3% missing), KRAS (2.3% missing) or BRAF (4.7% missing), we assigned a separate ("missing") indicator variable and included those cases in the multivariate analysis models. We confirmed that excluding cases with a missing variable did not significantly alter results (data not shown). There was no missing information in other variables.
###end p 41
###begin p 42
###xml 228 232 226 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
An association of each variable with CIMP-high was also assessed in strata of important clinical or molecular features, including age (<65 year old vs. >/=65 year old), sex, tumor location (proximal vs. distal), MSI status, and BRAF status. For stratified analysis, each multivariate logistic regression model included a variable of interest that was stratified by a given stratifying variable (e.g., age) and adjusted for all of the remaining variables (SAS codes available upon request).
###end p 42
###begin p 43
###xml 339 343 339 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
An interaction was assessed by including the cross product term of a given variable (e.g., MSI) and another variable of interest in a regression model, and the likelihood ratio test compared a model including the cross product term with that excluding it. In addition to interactions of any given variable with MSI, location, age, sex and BRAF, we examined all possible remaining two-way interactions, and found no significant interactions (data not shown).
###end p 43
###begin p 44
All statistical analyses except for clustering analysis used SAS version 9.1 (SAS Institute, Cary, NC). All p values were two-sided, and statistical significance was defined as p</=0.05. Nonetheless, multiple hypotheses testing was considered when interpreting the data, especially in examining multiple two-way interactions.
###end p 44
###begin title 45
Results
###end title 45
###begin title 46
Evaluation of 16 methylation markers
###end title 46
###begin p 47
###xml 91 98 91 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CACNA1G</italic>
###xml 100 104 100 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF2</italic>
###xml 106 113 106 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NEUROG1</italic>
###xml 115 120 115 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RUNX3</italic>
###xml 122 127 122 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOCS1</italic>
###xml 129 135 129 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 143 149 143 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRABP1</italic>
###xml 151 155 151 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 157 161 157 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHFR</italic>
###xml 163 167 163 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIC1</italic>
###xml 169 175 169 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 177 181 177 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MGMT</italic>
###xml 203 209 203 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 220 223 220 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WRN</italic>
###xml 254 258 254 258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Eads1">[30]</xref>
###xml 292 297 292 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOCS1</italic>
###xml 406 410 406 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Weisenberger1">[15]</xref>
###xml 447 451 447 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 515 519 515 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Ogino3">[24]</xref>
We obtained 904 colorectal cancer specimens and quantified DNA methylation in the 16 loci [CACNA1G, IGF2, NEUROG1, RUNX3, SOCS1, CDKN2A (p16), CRABP1, MLH1, CHFR, HIC1, IGFBP3, MGMT, MINT1, MINT31, p14 (CDKN2A/ARF), and WRN] by real-time PCR (MethyLight [30]) assays. The first 5 loci (up to SOCS1) were selected as good predictors of CIMP (CpG island methylator phenotype) by screening of 195 CpG islands [15]. The use of the first 8 loci (up to MLH1) as a CIMP-high diagnostic panel has been previously validated [24].
###end p 47
###begin p 48
###xml 203 207 203 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 212 216 212 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 282 290 282 290 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1</bold>
###xml 282 290 282 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003698-g001"><bold>Figure 1</bold></xref>
###xml 318 325 318 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CACNA1G</italic>
###xml 327 333 327 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 341 347 341 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRABP1</italic>
###xml 349 353 349 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF2</italic>
###xml 355 359 355 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 361 368 361 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NEUROG1</italic>
###xml 370 375 370 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RUNX3</italic>
###xml 380 385 380 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOCS1</italic>
###xml 578 581 578 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WRN</italic>
###xml 655 659 655 659 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MGMT</italic>
###xml 661 665 661 665 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIC1</italic>
###xml 667 671 667 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHFR</italic>
###xml 683 689 683 689 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 756 760 756 760 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 834 838 834 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Weisenberger1">[15]</xref>
###xml 840 844 840 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Samowitz1">[18]</xref>
###xml 846 850 846 850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Ogino3">[24]</xref>
###xml 958 962 958 962 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1153 1157 1153 1157 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1167 1171 1167 1171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Ogino5">[29]</xref>
###xml 1182 1195 1182 1195 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Supplemental </bold>
###xml 1195 1204 1195 1204 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure S1</bold>
###xml 1195 1204 1195 1204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003698.s001"><bold>Figure S1</bold></xref>
To evaluate 16 methylation markers in an unbiased fashion, we conducted an unsupervised hierarchical clustering analysis of the 16 methylation markers and status of MSI (microsatellite instability), and KRAS and BRAF oncogenes, using 860 tumors with all of these results available (Figure 1). The 8 CIMP-high markers (CACNA1G, CDKN2A (p16), CRABP1, IGF2, MLH1, NEUROG1, RUNX3 and SOCS1) were generally clustered together, indicating good concordance of methylation patterns in these markers and supporting these 8 markers as good CIMP-high markers. In addition, p14, MINT31 and WRN were also clustered with the 8 markers. The other 5 methylation markers (MGMT, HIC1, CHFR, MINT1 and IGFBP3) were not clustered closely with each other or the 8 markers. The BRAF and MSI variables, which have been known to be associated with CIMP-high [15], [18], [24], were also clustered together with these 8 markers, indicating tight associations with CIMP-high. Notably, KRAS mutation was not clustered with any of the methylation markers, suggesting its association with a random methylation pattern (particularly in CIMP-low tumors which have been associated with KRAS mutation [29]; see also Supplemental Figure S1). We used clustering analysis only for the examination of marker clustering, but not for tumor classification. That was because clustering of markers was very stable with the large number of tumors (i.e., excluding a few tumors did not substantially influence results) while tumor classification by clustering analysis based on the 16 markers was not stable.
###end p 48
###begin title 49
###xml 64 68 64 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 73 77 73 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
Hierarchical clustering analysis of 16 methylation makers, MSI, KRAS and BRAF in colorectal cancers.
###end title 49
###begin p 50
###xml 197 204 197 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CACNA1G</italic>
###xml 206 210 206 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF2</italic>
###xml 212 217 212 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RUNX3</italic>
###xml 219 223 219 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 225 230 225 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOCS1</italic>
###xml 232 238 232 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 246 252 246 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRABP1</italic>
###xml 257 264 257 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NEUROG1</italic>
###xml 393 397 393 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 427 431 427 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 520 524 520 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 569 573 569 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Ogino3">[24]</xref>
###xml 575 579 575 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Ogino5">[29]</xref>
Horizontal and vertical axes represent markers and cases, respectively. The expanded view of clustering tree for the markers is shown on the right. The 8 markers in our CIMP-high diagnostic panel (CACNA1G, IGF2, RUNX3, MLH1, SOCS1, CDKN2A (p16), CRABP1 and NEUROG1) are clustered closely, supporting that these markers are good CIMP-high markers. Also note the close relationship between MSI, BRAF and the 8 CIMP-high markers. KRAS mutation is not clustered with any of the methylation markers analyzed, suggesting that KRAS mutation (which is associated with CIMP-low [24], [29]; see Supplemental Figure) is probably associated with a random methylation pattern.
###end p 50
###begin p 51
###xml 226 239 222 235 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Supplemental </bold>
###xml 239 247 235 243 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table S1</bold>
###xml 239 247 235 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003698.s002"><bold>Table S1</bold></xref>
###xml 355 359 347 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 364 368 356 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 380 399 372 391 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Supplemental Figure</bold>
###xml 465 469 457 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 511 515 503 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 525 529 517 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Ogino3">[24]</xref>
###xml 531 535 523 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Ogino5">[29]</xref>
###xml 727 734 719 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CACNA1G</italic>
###xml 736 742 728 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 744 750 736 742 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRABP1</italic>
###xml 752 756 744 748 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF2</italic>
###xml 758 762 750 754 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 764 771 756 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NEUROG1</italic>
###xml 773 778 765 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RUNX3</italic>
###xml 783 788 775 780 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOCS1</italic>
###xml 881 886 869 874 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RUNX3</italic>
###xml 966 970 954 958 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHFR</italic>
###xml 972 976 960 964 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIC1</italic>
###xml 978 984 966 972 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 986 990 974 978 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MGMT</italic>
###xml 1015 1018 1003 1006 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WRN</italic>
To describe performance of each of the 16 markers in an unbiased way, we calculated kappa coefficient (for agreement statistics), sensitivity and specificity of each maker for CIMP-high diagnosis determined by the 16 markers (Supplemental Table S1). The cutoff for CIMP-high was set as >/=11/16 or >/=10/16 methylated markers based on the distribution of KRAS and BRAF mutations (Supplemental Figure), and on the previous findings that CIMP-high is associated with BRAF mutation and CIMP-low is associated with KRAS mutation [24], [29]. Sensitivity and specificity of each marker reflected overall concordance of a methylation pattern with the remaining 15 markers. It was evident that performance of the 8 CIMP-panel markers (CACNA1G, CDKN2A, CRABP1, IGF2, MLH1, NEUROG1, RUNX3 and SOCS1) was generally good. The kappa coefficient was greater than 0.5 for all of these 8 markers. RUNX3 was the single best marker for CIMP-high diagnosis. Among the other 8 markers (CHFR, HIC1, IGFBP3, MGMT, MINT1, MINT31, p14 and WRN), only MINT31 and p14 consistently showed the kappa coefficient greater than 0.5, and good sensitivity/specificity. This was in agreement with clustering analysis, which showed that MINT31 and p14 clustered with the 8 CIMP-panel markers.
###end p 51
###begin p 52
###xml 717 721 705 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Weisenberger1">[15]</xref>
###xml 820 824 808 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Ogino3">[24]</xref>
We also compared the all-16-marker panel with the 8-marker CIMP panel. Using the 8-maker panel, or the 16-maker panel, CIMP-high was defined as >/=6/8 or >/=11/16 methylated markers, respectively. Among the 904 cases, 879 cases (97.2%) showed concordant diagnosis of CIMP status between the 16-marker panel and the 8-marker panel (kappa = 0.89, p<0.0001). When the 16-marker CIMP panel was used, the associations of CIMP-high with clinical and molecular features were very similar to the CIMP-high associations by the 8-marker CIMP panel (data not shown). We also confirmed a high degree of agreement (98.6% concordant; kappa = 0.94) between the 8-marker panel and the 5-marker panel described by Weisenberger et al. [15]. Thus, in subsequent analyses, we used the 8-marker CIMP panel which we had extensively validated [24].
###end p 52
###begin title 53
CIMP-high in colorectal cancer
###end title 53
###begin p 54
###xml 88 95 88 95 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 1</bold>
###xml 88 95 88 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003698-t001"><bold>Table 1</bold></xref>
###xml 255 259 255 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 298 302 298 302 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
We assessed clinical, pathologic and molecular features of CIMP-high colorectal cancer (Table 1). By univariate analysis, CIMP-high was associated with female sex, older age, proximal location, poor differentiation, mucin, signet ring cells, MSI-high and BRAF mutation, and inversely with stage I, KRAS mutation, LINE-1 hypomethylation, positive p53, and active beta-catenin (all p<0.004).
###end p 54
###begin p 55
###xml 590 598 588 596 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2</bold>
###xml 590 598 588 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003698-g002"><bold>Figure 2</bold></xref>
###xml 677 685 675 683 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3</bold>
###xml 677 685 675 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003698-g003"><bold>Figure 3</bold></xref>
Age was linearly associated with CIMP-high in logistic regression analysis (p for trend <0.0001). We did not show significant non-linearity by the likelihood ratio test that compared a model including a quadratic (or cubic) term with a model excluding it (p>0.85). Likewise, LINE-1 hypomethylation was inversely linearly associated with CIMP-high (p for trend <0.0001), and there was no significant non-linearity by the likelihood ratio test, using a quadratic (or cubic) term (p>/=0.078). Non-parametric restricted cubic splines also supported a linear relation between age and CIMP-high (Figure 2) and an inverse linear relation between LINE-1 hypomethylation and CIMP-high (Figure 3).
###end p 55
###begin title 56
Smoothing spline for the age/CIMP-high association.
###end title 56
###begin p 57
###xml 3 4 3 4 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">e</sub>
Loge(OR for CIMP-high) (y axis) according to age (x axis) is shown (with young age as a referent). Broken lines indicate 95% confidence interval. Note the linear relation between age and CIMP-high. CIMP, CpG island methylator phenotype; OR, odds ratio.
###end p 57
###begin title 58
Smoothing spline for the LINE-1/CIMP-high association.
###end title 58
###begin p 59
###xml 3 4 3 4 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">e</sub>
Loge(OR for CIMP-high) (y axis) according to LINE-1 methylation (x axis) is shown (with high-level LINE-1 methylation as a referent). Broken lines indicate 95% confidence interval. Note the inverse linear relation between LINE-1 hypomethylation and CIMP-high. CIMP, CpG island methylator phenotype; LINE-1, long interspersed nucleotide element-1; OR, odds ratio.
###end p 59
###begin p 60
###xml 155 159 155 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 237 244 234 241 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 2</bold>
###xml 237 244 234 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003698-t002"><bold>Table 2</bold></xref>
###xml 324 328 321 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 666 670 663 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 715 722 712 719 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 2</bold>
###xml 715 722 712 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003698-t002"><bold>Table 2</bold></xref>
###xml 887 895 884 892 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4</bold>
###xml 887 895 884 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003698-g004"><bold>Figure 4</bold></xref>
In multivariate logistic regression analysis, CIMP-high was significantly associated with older age, proximal location, poor differentiation, MSI-high and BRAF mutation, and inversely with active beta-catenin and LINE-1 hypomethylation (Table 2). However, all of the other features (female, stage, mucin, signet ring cells, KRAS and p53) were no longer significantly associated with CIMP-high in multivariate analysis. We further examined for potential confounders in the association of each variable with CIMP-high. Except for sex, all of the other variables showed substantial changes in odds ratio (OR) for the association with CIMP-high after adjusting for MSI, BRAF and/or tumor location (or other variables) (Table 2). These results indicated the existence of complex relations between clinical and molecular features (including CIMP) in colorectal cancer, which are summarized in Figure 4.
###end p 60
###begin title 61
Summary of associations of CIMP-high with clinical and molecular features.
###end title 61
###begin p 62
The broken line indicates the relatively weak association.
###end p 62
###begin title 63
Associations with CIMP-high in strata of MSI
###end title 63
###begin p 64
###xml 86 90 86 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Jass2">[38]</xref>
###xml 91 95 91 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Popat1">[40]</xref>
###xml 222 229 222 229 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 3</bold>
###xml 222 229 222 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003698-t003"><bold>Table 3</bold></xref>
###xml 265 269 265 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 433 437 433 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 621 625 621 625 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
Molecular classification by MSI status is increasingly important in colorectal cancer [38]-[40]. Thus, we examined the relations of clinical and tumoral variables with CIMP-high in MSI-high tumors and non-MSI-high tumors (Table 3). Older age, proximal location and BRAF mutation were significantly associated with CIMP-high in both MSI-high and non-MSI-high tumors. In contrast, the relations of CIMP-high with poor differentiation, KRAS mutation and LINE-1 hypomethylation appeared to be different according to MSI status (p for interaction <0.005). CIMP-high was associated with poor differentiation and inversely with KRAS mutation in MSI-high tumors, but not in non-MSI-high tumors. LINE-1 hypomethylation was inversely associated with CIMP-high in non-MSI-high tumors, but not in MSI-high tumors.
###end p 64
###begin title 65
Associations with CIMP-high in MSI-high and non-MSI-high colorectal cancers.
###end title 65
###begin p 66
Each multivariate logistic regression model assesses a variable of interest (stratified by MSI status in a given model), adjusting for all of the above remaining variables. An interaction was assessed by the likelihood ratio test that compares a model including a cross product term (of the MSI variable and another variable of interest) with a model excluding it.
###end p 66
###begin p 67
###xml 223 227 212 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Jass1">[35]</xref>
beta-catenin activation is defined as beta-catenin score >/=3, where the beta-catenin score is the sum of nuclear (0, 1+ or 2+), cytoplasmic (0, 1+ or 2+) and membrane (0 or 1+) scores as originally described by Jass et al.[35].
###end p 67
###begin p 68
Proximal colon includes cecum to transverse colon, and distal colon includes splenic flexure to rectum.
###end p 68
###begin p 69
CI, confidence interval; CIMP, CpG island methylator phenotype; LINE-1, long interspersed nucleotide element-1; MSI, microsatellite instability; OR, odds ratio.
###end p 69
###begin title 70
Associations with CIMP-high in strata of tumor location
###end title 70
###begin p 71
###xml 105 109 105 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Jass2">[38]</xref>
###xml 111 115 111 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Sugai1">[41]</xref>
###xml 241 248 241 248 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 4</bold>
###xml 241 248 241 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003698-t004"><bold>Table 4</bold></xref>
There is accumulating evidence for a molecular difference between proximal and distal colorectal cancers [38], [41]. Therefore, we examined the relations of clinical and tumoral variables with CIMP-high in proximal tumors and distal tumors (Table 4). The relations of CIMP-high with the variables did not appear to differ according to tumor location (all p for interaction >0.23).
###end p 71
###begin title 72
Associations with CIMP-high in proximal and distal colorectal cancers.
###end title 72
###begin p 73
Each multivariate logistic regression model assesses a variable of interest (stratified by tumor location in a given model), adjusting for all of the above remaining variables. An interaction was assessed by the likelihood ratio test that compares a model including a cross product term (of the location variable and another variable of interest) with a model excluding it.
###end p 73
###begin p 74
###xml 223 227 212 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Jass1">[35]</xref>
beta-catenin activation is defined as beta-catenin score >/=3, where the beta-catenin score is the sum of nuclear (0, 1+ or 2+), cytoplasmic (0, 1+ or 2+) and membrane (0 or 1+) scores as originally described by Jass et al.[35].
###end p 74
###begin p 75
Proximal colon includes cecum to transverse colon, and distal colon includes splenic flexure to rectum.
###end p 75
###begin p 76
Because there was no CIMP-high beta-catenin-active tumors in distal colon, stable p for interaction and 95% CI for OR could not be estimated.
###end p 76
###begin p 77
CI, confidence interval; CIMP, CpG island methylator phenotype; LINE-1, long interspersed nucleotide element-1; MSI, microsatellite instability; OR, odds ratio.
###end p 77
###begin title 78
Associations with CIMP-high in other stratified analyses
###end title 78
###begin p 79
###xml 135 139 133 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 451 455 449 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 492 499 490 497 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 5</bold>
###xml 492 499 490 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003698-t005"><bold>Table 5</bold></xref>
###xml 592 596 590 594 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 688 692 686 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
We examined the relations of clinical and tumoral variables with CIMP-high in strata of sex, age (<65 year old vs. >/=65 year old) and BRAF status. Considering multiple hypotheses testing (12-hypotheses testing each), the effect of the variables did not appear to significantly differ according to age (all p for interaction >0.03) and sex (all p for interaction >0.02). Notably, the effect of LINE-1 hypomethylation did appear to differ according to BRAF status (p for interaction = 0.001) (Table 5). A significant inverse association of LINE-1 hypomethylation with CIMP-high was present in BRAF-mutated tumors [adjusted OR = 0.022; 95% confidence interval (CI), 0.003-0.17], but not in BRAF-wild-type tumors (adjusted OR = 0.87; 95% CI, 0.25-3.06).
###end p 79
###begin title 80
###xml 31 35 31 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 50 54 50 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
Associations with CIMP-high in BRAF-wild-type and BRAF-mutated colorectal cancers.
###end title 80
###begin p 81
###xml 91 95 91 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 292 296 292 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
Each multivariate logistic regression model assesses a variable of interest (stratified by BRAF status in a given model), adjusting for all of the above remaining variables. An interaction was assessed by the likelihood ratio test that compares a model including a cross product term (of the BRAF variable and another variable of interest) with a model excluding it.
###end p 81
###begin p 82
###xml 223 227 212 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Jass1">[35]</xref>
beta-catenin activation is defined as beta-catenin score >/=3, where the beta-catenin score is the sum of nuclear (0, 1+ or 2+), cytoplasmic (0, 1+ or 2+) and membrane (0 or 1+) scores as originally described by Jass et al.[35].
###end p 82
###begin p 83
Proximal colon includes cecum to transverse colon, and distal colon includes splenic flexure to rectum.
###end p 83
###begin p 84
CI, confidence interval; CIMP, CpG island methylator phenotype; LINE-1, long interspersed nucleotide element-1; MSI, microsatellite instability; OR, odds ratio.
###end p 84
###begin p 85
We also examined all of the remaining potential two-way interactions by the available clinical and tumoral variables, and found no significant interactions with regard to the associations with CIMP-high (data not shown).
###end p 85
###begin title 86
Discussion
###end title 86
###begin p 87
###xml 155 162 155 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CACNA1G</italic>
###xml 164 168 164 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF2</italic>
###xml 170 177 170 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NEUROG1</italic>
###xml 179 184 179 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RUNX3</italic>
###xml 189 194 189 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOCS1</italic>
###xml 247 251 247 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Weisenberger1">[15]</xref>
###xml 341 347 341 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 349 355 349 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRABP1</italic>
###xml 360 364 360 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 366 370 366 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Ogino3">[24]</xref>
###xml 532 536 532 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
In this study utilizing a large sample size, we evaluated 16 methylation makers in an unbiased fashion. The 16 methylation markers included the 5 markers (CACNA1G, IGF2, NEUROG1, RUNX3 and SOCS1) that were selected by screening of 195 CpG islands [15] and further validated to be included in the CIMP-high diagnostic panel (the above 5 plus CDKN2A, CRABP1 and MLH1) [24]. By unsupervised hierarchical clustering analysis, the 5 methylation markers were clustered with each other as well as with MSI (microsatellite instability) and BRAF mutation. Analysis of kappa coefficient, sensitivity and specificity also demonstrated good performance of the 5 methylation markers with generally concordant methylation pattern. Utilizing the validated CIMP panel, we have deciphered the complex relations of CIMP-high with various clinical, pathologic and molecular features in colorectal cancer. Our data provide a rationale for the of the validated CIMP-specific methylation marker panel.
###end p 87
###begin p 88
###xml 87 91 87 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Weisenberger1">[15]</xref>
###xml 195 202 195 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CACNA1G</italic>
###xml 204 208 204 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGF2</italic>
###xml 210 217 210 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NEUROG1</italic>
###xml 219 224 219 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RUNX3</italic>
###xml 230 235 230 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SOCS1</italic>
###xml 238 244 238 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CRABP1</italic>
###xml 249 253 249 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLH1</italic>
###xml 291 294 291 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WRN</italic>
###xml 303 307 303 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CHFR</italic>
###xml 309 315 309 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IGFBP3</italic>
###xml 317 321 317 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HIC1</italic>
###xml 326 330 326 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MGMT</italic>
###xml 340 346 340 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CDKN2A</italic>
###xml 508 512 508 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
This study is the first extensive investigation to compare the 5 new CIMP-high markers [15] with MINT1, MINT31 and other CpG islands, using a large sample size. Performance of the 5 new markers (CACNA1G, IGF2, NEUROG1, RUNX3, and SOCS1), CRABP1 and MLH1 was consistently superior to that of WRN, MINT1, CHFR, IGFBP3, HIC1 and MGMT. MINT31, CDKN2A, and p14 showed intermediate performance characteristics, and in hierarchical clustering analysis, were generally clustered with the new 5 CIMP markers, MSI and BRAF mutation. We have provided valuable data for standardization of methylation markers for the detection of CIMP-high in colorectal cancer.
###end p 88
###begin p 89
###xml 76 80 76 80 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Sengupta1">[42]</xref>
###xml 81 85 81 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Firestein1">[46]</xref>
###xml 131 135 131 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Eads1">[30]</xref>
###xml 284 288 284 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Ogino6">[31]</xref>
Studying epigenetic and genetic aberrations is important in cancer research [42]-[46]. We used quantitative PCR assays (MethyLight [30]) to determine the degree of DNA methylation, which is robust enough to reproducibly differentiate low-level methylation from high-level methylation [31]. Our resource of a large colorectal cancer sample obtained from two large prospective cohorts (representing a relatively unbiased sample compared to a single-hospital-based sample) has provided a sufficient power to evaluate the 16 methylation markers, and to simultaneously assess independent relations of CIMP-high with multiple clinical and tumoral molecular variables.
###end p 89
###begin p 90
###xml 93 97 93 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 207 211 207 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Ogino3">[24]</xref>
###xml 213 217 213 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Ogino5">[29]</xref>
###xml 219 223 219 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 376 380 376 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 588 592 588 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 664 668 664 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
Interestingly, unsupervised clustering analysis using a large number of tumors revealed that KRAS mutation was not clustered with any of the 16 methylation markers. However, as shown in our previous studies [24], [29], KRAS mutation was more common in CIMP-low tumors compared to CIMP-high and CIMP-0 tumors. Although these findings appeared to be discrepant, we believe that KRAS mutation is perhaps associated with a random pattern of CpG island methylation, indicated by the non-clustering phenomenon in clustering analysis. In contrast, our clustering analysis has clearly shown that BRAF mutation is clustered with CIMP-high specific markers, indicating that BRAF mutation is perhaps associated with a non-random pattern of CpG island methylation.
###end p 90
###begin p 91
###xml 175 179 175 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 200 204 200 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 239 242 236 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APC</italic>
###xml 289 293 286 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TP53</italic>
###xml 293 296 290 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-vanRijnsoever1">[9]</xref>
###xml 297 301 294 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Kawasaki1">[19]</xref>
###xml 303 307 300 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Ogino2">[21]</xref>
###xml 309 313 306 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Samowitz2">[47]</xref>
###xml 315 319 312 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Suehiro1">[48]</xref>
###xml 729 737 726 734 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3</bold>
###xml 729 737 726 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003698-g003"><bold>Figure 3</bold></xref>
###xml 1191 1195 1188 1192 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 1250 1257 1247 1254 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 2</bold>
###xml 1250 1257 1247 1254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0003698-t002"><bold>Table 2</bold></xref>
###xml 1293 1297 1290 1294 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 1051 1058 <span type="species:ncbi:9606">patient</span>
Previous studies identified various factors associated with CIMP-high, including old age, female, proximal location, poor differentiation, mucin, signet ring cells, MSI-high, BRAF mutation, wild-type KRAS, inactive beta-catenin, wild-type APC, high LINE-1 methylation level, and wild-type TP53[9]-[19], [21], [47], [48]. However, many of these factors are interrelated. Thus, in order to properly decipher the relations with CIMP-high, it is necessary to use a large number of tumors, determine a number of molecular features, and perform comprehensive biostatistical analysis. We were able to utilize a large colorectal cancer sample that has been examined for multiple molecular events, and appropriate biostatistical methods. Figure 3 summarizes our current knowledge on the associations of clinical, pathologic and molecular features including CIMP in colorectal cancer. It is very important to keep in mind these relations, when analyzing the association between any of these factors and an outcome (e.g., molecular changes in colorectal cancer, patient mortality, etc.). These factors may confound the relationship of interest. Indeed, we have demonstrated confounding effects of MSI, BRAF and tumor location in a number of the associations in Table 2. In particular, signet ring cells, KRAS and p53 were no longer associated with CIMP-high after adjusting for the confounders.
###end p 91
###begin p 92
###xml 74 78 74 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KRAS</italic>
###xml 214 218 214 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Jass2">[38]</xref>
###xml 219 223 219 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Popat1">[40]</xref>
###xml 337 343 337 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TGFBR2</italic>
###xml 348 351 348 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BAX</italic>
###xml 351 355 351 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Markowitz1">[49]</xref>
###xml 357 361 357 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Rampino1">[50]</xref>
We have shown that the relations of CIMP-high with tumor differentiation, KRAS mutation and LINE-1 hypomethylation appear to differ according to MSI status. MSI is a major molecular classifier in colorectal cancer [38]-[40]. MSI-high tumors have been shown to exhibit widespread mutations in nucleotide repeat sequences such as those in TGFBR2 and BAX[49], [50]. Thus, it is likely that overall genomic changes in MSI-high tumors are dissimilar to those of non-MSI-high tumors. That may explain why there are some pathologic and molecular features that are differentially associated with CIMP-high according to MSI status.
###end p 92
###begin p 93
In summary, using the 16 methylation markers and a large population-based sample, we have evaluated performance of each of the 16 methylation markers in an unbiased fashion. Our current study provides valuable data for standardization of the use of CIMP-high-specific markers. Using the validated CIMP-specific methylation marker panel, we have comprehensively analyzed the clinical, pathologic and molecular features of CIMP-high colorectal cancer by comprehensive biostatistical methods. We have provided the rationale to use the validated CIMP-high-specific methylation marker panel in clinical and research settings. Further studies are necessary to elucidate fundamental molecular defects that lead to CIMP-high colorectal cancer.
###end p 93
###begin title 94
Supporting Information
###end title 94
###begin p 95
###xml 288 292 288 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Ogino3">[24]</xref>
###xml 294 298 294 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003698-Ogino5">[29]</xref>
Distribution of colorectal cancers according to the number of methylated markers and KRAS/BRAF mutational status. Note that KRAS mutation is associated with CIMP-low (rather than CIMP-high and CIMP-negative), in agreement with studies using more limited CIMP-specific methylation markers [24], [29].
###end p 95
###begin p 96
(0.12 MB TIF)
###end p 96
###begin p 97
Click here for additional data file.
###end p 97
###begin p 98
Markers are listed in the order of the kappa coefficient. * Sensitivity of each marker is defined as "[the number of CIMP-high cases positive for a given marker] / [the number of all CIMP-high cases]". wedge Specificity of each marker is defined as "[the number of non-CIMP-high cases negative for a given marker] / [the number of all non-CIMP-high cases]".
###end p 98
###begin p 99
(0.15 MB DOC)
###end p 99
###begin p 100
Click here for additional data file.
###end p 100
###begin p 101
###xml 89 101 <span type="species:ncbi:9606">participants</span>
We deeply thank the Nurses' Health Study and Health Professionals Follow-up Study cohort participants who have generously agreed to provide us with biological specimens and information through responses to questionnaires; hospitals and pathology departments throughout the U.S. for generously providing us with tumor tissue materials; Frank Speizer, Walter Willett, Graham Colditz, Susan Hankinson, and many other staff members who implemented and have maintained the cohort studies.
###end p 101
###begin title 102
References
###end title 102
###begin article-title 103
The epigenomics of cancer.
###end article-title 103
###begin article-title 104
Epigenetics in cancer.
###end article-title 104
###begin article-title 105
Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?
###end article-title 105
###begin article-title 106
CpG island methylator phenotype in cancer.
###end article-title 106
###begin article-title 107
CpG island methylator phenotype in colorectal cancer.
###end article-title 107
###begin article-title 108
CIMP and colon cancer gets more complicated.
###end article-title 108
###begin article-title 109
CpG island methylator phenotype (CIMP) in cancer: Causes and implications.
###end article-title 109
###begin article-title 110
Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype.
###end article-title 110
###begin article-title 111
Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands.
###end article-title 111
###begin article-title 112
Morphological and molecular heterogeneity within nonmicrosatellite instability-high colorectal cancer.
###end article-title 112
###begin article-title 113
CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability.
###end article-title 113
###begin article-title 114
BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum.
###end article-title 114
###begin article-title 115
Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation.
###end article-title 115
###begin article-title 116
APC gene methylation is inversely correlated with features of the CpG island methylator phenotype in colorectal cancer.
###end article-title 116
###begin article-title 117
CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer.
###end article-title 117
###begin article-title 118
The CpG Island Methylator Phenotype and Chromosomal Instability Are Inversely Correlated in Sporadic Colorectal Cancer.
###end article-title 118
###begin article-title 119
CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies.
###end article-title 119
###begin article-title 120
Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer.
###end article-title 120
###begin article-title 121
Correlation of beta-catenin localization with cyclooxygenase-2 expression and CpG island methylator phenotype (CIMP) in colorectal cancer.
###end article-title 121
###begin article-title 122
Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer.
###end article-title 122
###begin article-title 123
LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG methylator phenotype in colorectal cancer.
###end article-title 123
###begin article-title 124
Integrated analysis of chromosomal, microsatellite and epigenetic instability in colorectal cancer identifies specific associations between promoter methylation of pivotal tumour suppressor and DNA repair genes and specific chromosomal alterations.
###end article-title 124
###begin article-title 125
Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases.
###end article-title 125
###begin article-title 126
Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample.
###end article-title 126
###begin article-title 127
###xml 53 58 <span type="species:ncbi:9606">women</span>
The Nurses' Health Study: lifestyle and health among women.
###end article-title 127
###begin article-title 128
Aspirin and the Risk of Colorectal Cancer in Relation to the Expression of COX-2.
###end article-title 128
###begin article-title 129
CpG island methylator phenotype-low (CIMP-low) colorectal cancer shows not only few methylated CIMP-high-specific CpG islands, but also low-level methylation at individual loci.
###end article-title 129
###begin article-title 130
Sensitive sequencing method for KRAS mutation detection by Pyrosequencing.
###end article-title 130
###begin article-title 131
CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations.
###end article-title 131
###begin article-title 132
MethyLight: a high-throughput assay to measure DNA methylation.
###end article-title 132
###begin article-title 133
Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis.
###end article-title 133
###begin article-title 134
A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements.
###end article-title 134
###begin article-title 135
LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability.
###end article-title 135
###begin article-title 136
Loss of nuclear p27 (CDKN1B/KIP1) in colorectal cancer is correlated with microsatellite instability and CIMP.
###end article-title 136
###begin article-title 137
Characterisation of a subtype of colorectal cancer combining features of the suppressor and mild mutator pathways.
###end article-title 137
###begin article-title 138
TM4 microarray software suite.
###end article-title 138
###begin article-title 139
Flexible regression models with cubic splines.
###end article-title 139
###begin article-title 140
Classification of colorectal cancer based on correlation of clinical, morphological and molecular features.
###end article-title 140
###begin article-title 141
Molecular classification and correlates in colorectal cancer.
###end article-title 141
###begin article-title 142
Systematic Review of Microsatellite Instability and Colorectal Cancer Prognosis.
###end article-title 142
###begin article-title 143
Analysis of molecular alterations in left- and right-sided colorectal carcinomas reveals distinct pathways of carcinogenesis: proposal for new molecular profile of colorectal carcinomas.
###end article-title 143
###begin article-title 144
Artificially introduced aneuploid chromosomes assume a conserved position in colon cancer cells.
###end article-title 144
###begin article-title 145
Novel decapeptides that bind avidly and deliver radioisotope to colon cancer cells.
###end article-title 145
###begin article-title 146
Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling.
###end article-title 146
###begin article-title 147
Chromosomal instability in near-diploid colorectal cancer: a link between numbers and structure.
###end article-title 147
###begin article-title 148
The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth.
###end article-title 148
###begin article-title 149
APC mutations and other genetic and epigenetic changes in colon cancer.
###end article-title 149
###begin article-title 150
Epigenetic-Genetic Interactions in the APC/WNT, RAS/RAF, and P53 Pathways in Colorectal Carcinoma.
###end article-title 150
###begin article-title 151
Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability.
###end article-title 151
###begin article-title 152
Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype.
###end article-title 152
###begin p 153
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 153
###begin p 154
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This work was supported by U.S. National Institute of Health (NIH) grants P01 CA87969, P01 CA55075, P50 CA127003 and K07 CA122826 (to S.O.), and in part by grants from the Bennett Family Fund and from the Entertainment Industry Foundation (EIF) through the EIF National Colorectal Cancer Research Alliance (NCCRA). K.N. was supported by a fellowship grant from the Japanese Society for Promotion of Science. The content is solely the responsibility of the authors and does not necessarily represent the official views of NCI or NIH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 154

